HOYA Vision Care is intensifying its commitment to combat childhood myopia progression globally through innovative solutions. While most research on childhood myopia occurs in East Asia, where the condition is most prevalent, the rising global prevalence necessitates testing solutions in diverse populations. To address this, the HOYA Global Medical Affairs team initiated a 3-year observational study in the UK, aiming to extend the benefits of MiYOSMART to European children.
One year into the study, presented at the ARVO 2023 conference, results from 128 children aged 5 to 15 revealed the effectiveness of MiYOSMART spectacle lenses in both Caucasian and Asian children, particularly those aged 8 to 13. The lenses demonstrated comparable effectiveness, with most children symptom-free within a week, highlighting great tolerability and acceptance.
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care, expressed excitement over the interim results, emphasizing MiYOSMART as a globally effective solution. The commitment to evidence-based myopia management is underscored by HOYA Vision Care’s Confidence through Evidence campaign, launched in October 2023.
This campaign educates Eye Care Professionals on evidence’s significance in childhood myopia management and highlights MiYOSMART’s robust evidence. Professor Saw Seang Mei from the Singapore Eye Research Institute emphasized the importance of evidence-based treatments in managing childhood myopia.
With over 2 million parents trusting MiYOSMART since its 2018 launch, the evidence portfolio expanding to a European cohort underscores HOYA Vision Care’s dedication to addressing the growing global myopia problem. The company aims to empower Eye Care Professionals through evidence-based practices, shaping the future of myopia management.
